Compare Domino's Pizza, Inc. (DPZ) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Summit Therapeutics Inc — how do they compare? Domino's Pizza, Inc. trades at $309.36 (market cap $10.21B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Domino's Pizza, Inc. pays a 2.58% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Summit Therapeutics Inc for 16 Days on average.
| DPZ | SMMT | |
|---|---|---|
Market Cap | $10.21B | $13.71B |
Volume | 916,737 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $26.38 |
52-Week Low | $282.89 | $12.43 |
Typical Hold Time | 106 Days | 16 Days |
Enterprise Value | $15.17B | $13.04B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DPZ trades at $308.65, up 1.83% today, with a bullish technical signal but recent earnings misses. Revenue grew to $4.94B in 2025 with a net income margin of 11.86%, though the company carries significant debt. Analyst consensus is a Buy with a $373 price target, but news highlights concerns over dividend growth and store closures.
The outlook is mixed: strong profitability and analyst support suggest upside, but high debt and recent underperformance pose risks. Investors should weigh solid fundamentals against execution challenges and macroeconomic pressures on the restaurant sector.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
